DexCom stock is trading -10.49% below its average target price of $141.91 after marking a 2.9% during today's afternoon session. Analysts are giving the large-cap Medical Instruments & Supplies company an average rating of buy and target prices ranging from $115.0 to $152.0 per share.
The stock has an average amount of shares sold short at 4.2%, and a short ratio of 5.58. The company's insiders own 0.41% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.1% of DexCom's shares being owned by this investor type.
Institutions Invested in DexCom
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Vanguard Group, Inc. (The) | 11% | 44,111,845 | $5,603,527,616 |
| 2023-03-31 | Blackrock Inc. | 9% | 33,266,336 | $4,225,822,621 |
| 2023-03-31 | Baillie Gifford and Company | 4% | 17,157,499 | $2,179,517,077 |
| 2023-03-31 | State Street Corporation | 4% | 16,143,716 | $2,050,736,223 |
| 2023-03-31 | Sands Capital Management, LLC | 4% | 13,738,968 | $1,745,261,088 |
| 2023-03-31 | FMR, LLC | 3% | 10,807,868 | $1,372,923,458 |
| 2023-03-31 | JP Morgan Chase & Company | 3% | 10,764,828 | $1,367,456,087 |
| 2023-03-31 | Capital Research Global Investors | 2% | 9,274,615 | $1,178,154,332 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 8,282,663 | $1,052,146,670 |
| 2023-03-31 | Nuveen Asset Management, LLC | 2% | 7,857,922 | $998,191,822 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on DexCom.
